{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:50:29Z","timestamp":1791993029011,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11606-026-10181-4","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:43:00Z","timestamp":1769697780000},"page":"2807-2814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk Factors for Falls in Older Depressed Adults Treated with Bupropion: An Analysis of the OPTIMUM Randomized Clinical Trial"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-2110","authenticated-orcid":false,"given":"David A.","family":"Bender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit H.","family":"Mulsant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Lavretsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles F.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lenard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Yingling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Phillip","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan D.","family":"Kharasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lenze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"10181_CR1","unstructured":"Pollock BG. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry 1999;60(Suppl 20):4-8."},{"key":"10181_CR2","doi-asserted-by":"crossref","unstructured":"Bansal N et al. Antidepressant use and risk of adverse outcomes: population-based cohort study. BJPsych Open 2022;8(5):e164.","DOI":"10.1192\/bjo.2022.563"},{"key":"10181_CR3","doi-asserted-by":"crossref","unstructured":"Gebara MA et al. Cause or Effect? Selective Serotonin Reuptake Inhibitors and Falls in Older Adults: A Systematic Review. Am J Geriatr Psychiatry 2015;23(10): 1016-28","DOI":"10.1016\/j.jagp.2014.11.004"},{"key":"10181_CR4","doi-asserted-by":"crossref","unstructured":"Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005;293(20): 2462","DOI":"10.1001\/jama.293.20.2462"},{"key":"10181_CR5","doi-asserted-by":"crossref","unstructured":"James SL et al. The global burden of falls: global, regional and national estimates of morbidity and mortality from the Global Burden of Disease Study 2017. Inj Prev 2020;26(Supp 1): i3-i11.","DOI":"10.1136\/injuryprev-2019-043484corr1"},{"key":"10181_CR6","doi-asserted-by":"crossref","unstructured":"Florence CS et al. Medical Costs of Fatal and Nonfatal Falls in Older Adults. J Am Geriatr Soc 2018;66(4): 693-698.","DOI":"10.1111\/jgs.15304"},{"key":"10181_CR7","doi-asserted-by":"crossref","unstructured":"Jia H et al. Prevalence, risk factors, and burden of disease for falls and balance or walking problems among older adults in the U.S. Prev Med 2019;126: 105737","DOI":"10.1016\/j.ypmed.2019.05.025"},{"key":"10181_CR8","doi-asserted-by":"crossref","unstructured":"Na I et al. Risk of Falls Associated with Long-Acting Benzodiazepines or Tricyclic Antidepressants Use in Community-Dwelling Older Adults: A Nationwide Population-Based Case-Crossover Study. Int J Environ Res Public Health 2022;19(14).","DOI":"10.3390\/ijerph19148564"},{"key":"10181_CR9","doi-asserted-by":"crossref","unstructured":"Capiau A et al. Therapeutic dilemmas with benzodiazepines and Z-drugs: insomnia and anxiety disorders versus increased fall risk: a clinical review. Eur Geriatr Med 2023;14(4): 697-708.","DOI":"10.1007\/s41999-022-00731-4"},{"key":"10181_CR10","doi-asserted-by":"crossref","unstructured":"Ray WA, Thapa PB, and Gideon P. Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 2000;48(6): 682-5.","DOI":"10.1111\/j.1532-5415.2000.tb04729.x"},{"key":"10181_CR11","doi-asserted-by":"crossref","unstructured":"Seppala LJ et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics. J Am Med Dir Assoc 2018;19(4): 371 e11-371 e17.","DOI":"10.1016\/j.jamda.2017.12.098"},{"key":"10181_CR12","doi-asserted-by":"crossref","unstructured":"van Poelgeest EP et al. Depression, antidepressants and fall risk: therapeutic dilemmas-a clinical review. Eur Geriatr Med, 2021;12(3): 585-596.","DOI":"10.1007\/s41999-021-00475-7"},{"key":"10181_CR13","doi-asserted-by":"crossref","unstructured":"Iaboni A and Mulsant BH. Why Do Older Adults Taking Antidepressants Fall? Am J Geriatr Psychiatry 2020;28(3): 285-287.","DOI":"10.1016\/j.jagp.2019.11.001"},{"key":"10181_CR14","doi-asserted-by":"crossref","unstructured":"Joo JH et al. Risk factors for falls during treatment of late-life depression. J Clin Psychiatry 2002;63(10): 936-41.","DOI":"10.4088\/JCP.v63n1012"},{"key":"10181_CR15","doi-asserted-by":"crossref","unstructured":"Berry SD et al Antidepressant prescriptions: an acute window for falls in the nursing home. J Gerontol A BiolSci Med Sci 2011;66(10): 1124-30.","DOI":"10.1093\/gerona\/glr113"},{"key":"10181_CR16","doi-asserted-by":"crossref","unstructured":"Kerse N et al. Falls, depression and antidepressants in later life: a large primary care appraisal. PLoS One 2008;3(6): e2423.","DOI":"10.1371\/journal.pone.0002423"},{"key":"10181_CR17","doi-asserted-by":"crossref","unstructured":"Mahoney JE, et al. Temporal association between hospitalization and rate of falls after discharge. Arch Intern Med, 2000;160(18): 2788-95.","DOI":"10.1001\/archinte.160.18.2788"},{"key":"10181_CR18","doi-asserted-by":"crossref","unstructured":"Monarrez-Espino J et al. Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study. Nicotine Tob Res 2018;20(5): 606-613.","DOI":"10.1093\/ntr\/ntx131"},{"key":"10181_CR19","doi-asserted-by":"crossref","unstructured":"Naples JG et al, Non-tricyclic and Non-selective Serotonin Reuptake Inhibitor Antidepressants and Recurrent Falls in Frail Older Women. Am J Geriatr Psychiatry 2016;24(12): 1221-1227.","DOI":"10.1016\/j.jagp.2016.08.008"},{"key":"10181_CR20","doi-asserted-by":"crossref","unstructured":"Wang GH et al. Injurious Fall Risk Differences Among Older Adults With First-Line Depression Treatments. JAMA Netw Open 2024;7(8): e2435535","DOI":"10.1001\/jamanetworkopen.2024.35535"},{"key":"10181_CR21","unstructured":"Wellbutrin (bupropion hydrochloride) Tablets. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018644s043lbl.pdf"},{"key":"10181_CR22","doi-asserted-by":"crossref","unstructured":"Lenze EJ, et al. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. N Engl J Med, 2023;388(12): 1067-1079.","DOI":"10.1056\/NEJMoa2204462"},{"key":"10181_CR23","doi-asserted-by":"crossref","unstructured":"Alexopoulos GS, et al. Pharmacotherapy of depression in older patients: a summary of the expert consensus guidelines. J Psychiatr Pract 2001;7(6): 361-76.","DOI":"10.1097\/00131746-200111000-00003"},{"key":"10181_CR24","doi-asserted-by":"crossref","unstructured":"Kharasch ED and Lenze EJ. Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion. Drug Metab Dispos 2024;52(5): 455-466","DOI":"10.1124\/dmd.124.001697"},{"key":"10181_CR25","doi-asserted-by":"crossref","unstructured":"Miller MD et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41(3):237-48.","DOI":"10.1016\/0165-1781(92)90005-N"},{"key":"10181_CR26","doi-asserted-by":"crossref","unstructured":"Rose M et al. The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiency. J ClinEpidemiol 2014;67(5): 516-26","DOI":"10.1016\/j.jclinepi.2013.10.024"},{"key":"10181_CR27","doi-asserted-by":"crossref","unstructured":"Tinetti ME, Speechley M and Ginter SF Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319(26): 1701-7.","DOI":"10.1056\/NEJM198812293192604"},{"key":"10181_CR28","doi-asserted-by":"crossref","unstructured":"Kharasch ED et al. Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults. Clin Pharmacol Ther 2020;108(5): 1036-1048.","DOI":"10.1002\/cpt.1888"},{"key":"10181_CR29","doi-asserted-by":"crossref","unstructured":"Sager JE, et al. In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol 2017;123: 85-96.","DOI":"10.1016\/j.bcp.2016.11.007"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10181-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10181-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10181-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:37:38Z","timestamp":1785350258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10181-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10181"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10181-4","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was a secondary analysis of the OPTIMUM clinical trial and did not require additional ethical approval. Information on the OPTIMUM clinical trial have been previously published.\n                      22","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants in the OPTIMUM clinical trial were consented.\n                      22","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Bender has no conflicts of interest to report. Dr. Mulsant holds and receives support from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He currently receives or has received with the past three years research support from Brain Canada, the Canadian Institutes of Health Research (CIHR), the CAMH Foundation, the Patient-Centered Outcomes Research Institute (PCORI), the US National Institute of Health (NIH), and HAPPYneuron (software used in a study founded by Brain Canada). Dr. Lavretsky has received research funding from the NIH, participated on a Data Safety Monitoring Board for an project funded by the NIA, receives royalties from Oxford University Press, and serves as the President of the AAGP. Dr. Brown has received consulting fees from NIMH funded researchers (the BAARD project) and coordinates a NIMH T32 training program. Dr. Karp has received research funding from Johnson and Johnson Neuroscience, PCORI, and NIH. He has received consulting fees from Biogen, Johnson and Johnson Neuroscience, Otsuka, and Aifred Health. He is the Secretary\/Treasurer Elect of the American Association for Geriatric Psychiatry. Dr. Reynolds has no conflicts of interest to report. Emily Lenard has no conflicts of interest to report. Michael Yingling has no conflicts of interest to report. J. Phillip Miller has participated on data safety monitoring board or advisory boards for a trial of vamorolone for the treatment of Becker Muscular Dystrophy, a trial of escitalopram studying biomarkers, and a study of Phase 1\/2a study of 2-Hydroxypropyl-\u03b2-Cyclodextrin Therapy for Infantile Liver Disease Associated with Niemann-Pick Disease, type C. In the past 36\u00a0months, Dr. Nicol has received salary support from institutional grants supported by the National Center for Translational Sciences (NCATS) and the National Institute of Digestive and Diabetes and Kidney Diseases (NIDDK); research support from the National Institute of Mental Health (NIMH), the Health Resources and Services Administration (HRSA), the Taylor the McDonnell Center for Systems Neuroscience, and the Center for Holistic Interdisciplinary Research on Psychedelics (CHIRP) at Washington University. She has served as a Co-Investigator or Principal Investigator for studies funded by COMPASS Pathways, LB Pharmaceuticals, Inc., Usona Institute and Alkermes, Inc., and has received personal fees as a consultant for Carelon, Novartis and Alkermes, Inc. Dr. Kharasch serves on the Data Safety and Monitoring board for Vertex Pharma. Dr. Lenze\u00a0has received research support from the Balvi Foundation, the XPrize Foundation, and Pritikin ICR.","order":4,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, or the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. Clinicaltrials.gov registration number: NCT02960763.","order":5,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}]}}